Browse the corpus

Eletriptan is a medication approved by the U.S. Food and Drug Administration (FDA) to treat acute migraine headaches in adults, with or without aura. This drug belongs to a class of medications commonly known as 'triptans,' which are serotonin receptor agonists. Eletriptan demonstrated notable affinity and selectivity for the 5-HT(1B/1D) receptors, which have a crucial role in the pathophysiology of migraines. Eletriptan effectively induces vasoconstriction in the cerebral arteries, mitigating the pain associated with migraine headaches attributed to vasodilation of the cerebral arteries. This activity primarily focuses on elucidating the indications, mechanism of action, administration procedures, and contraindications associated with eletriptan treatment. This activity also highlights the importance of the interprofessional healthcare team in delivering effective patient care by enhancing clinicians' competence while administering eletriptan and ensuring the best possible outcomes for migraine patients. Objectives: Identify the appropriate indications for eletriptan use in the acute treatment of migraine headaches with or without aura in adults. Screen patients for potential comorbid conditions and drug-drug interactions that may impact the safe and effective use of eletriptan. Apply knowledge of eletriptan metabolism via CYP3A4 enzymes to anticipate and manage potential drug interactions, ensuring patient safety. Collaborate with the interprofessional healthcare team, including neurologists, headache specialists, nurses, and pharmacists, to enhance collective competence to optimize treatment outcomes and minimize adverse events associated with eletriptan use. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The most prevalent signs and symptoms of eletriptan overdose align with those of other triptans, including chest pain or tightness, jaw or neck pain or tightness, shortness of breath, palpitations, dizziness, nausea, vomiting, and sweating.[32] These symptoms may indicate severe cardiovascular complications, such as myocardial ischemia due to coronary vasospasm, arrhythmia, or hypertensive crisis or emergency. Non-ST-elevation myocardial infarction (NSTEMI) due to eletriptan overdose has been reported.[48] Other possible signs and symptoms of eletriptan overdose include headache, confusion, agitation, hallucinations, seizures, coma, stroke, cerebral hemorrhage or ischemia, peripheral vascular ischemia or infarction, gastrointestinal ischemia or infarction, renal failure, liver failure, and death. Eletriptan overdose can also induce serotonin syndrome, a rare but potentially fatal condition arising from an excess of serotonin in the body. Serotonin syndrome can be triggered by the concurrent use of eletriptan with other medications that elevate serotonin levels, including antidepressants, opioids, or other triptans. The symptoms of serotonin syndrome include restlessness, agitation, confusion, hallucinations, fever, sweating, shivering, muscle stiffness or twitching, tremors, ataxia, nausea, vomiting, diarrhea, and arrhythmias. National Poison Data System data analysis indicates a low risk of severe effects or death resulting from triptan toxicity. Triptan toxidrome is characterized by tachycardia, hypertension, and drowsiness. The study also identifies a higher risk of mortality associated with advanced age and simultaneous use of benzodiazepines or tricyclic antidepressants.[49] Management of Overdose Although a specific antidote for triptan toxicity does not exist, it is recommended to discontinue eletriptan therapy and initiate cyproheptadine therapy, if toxicity is suspected, particularly in the case of serotonin syndrome. Notably, eletriptan toxicity is associated with a low risk of death.[49] In managing eletriptan toxicity, the primary approaches involve decontamination, supportive care, airway management, monitoring patient vitals, and consulting with a medical toxicologist in cases of significant overdose. Due to the large volume of drug distribution, hemodialysis is unlikely to be effective.

Migraines are incapacitating headaches that can persist for up to 72 hours if left untreated or treated inadequately. Patients commonly encounter accompanying symptoms such as nausea and vomiting, photophobia, and phonophobia, all of which can significantly impact the individual's daily functioning. Therefore, although the treatment of migraines is multifactorial, it is essential.[50] Quality patient education is integral to the success of migraine management plans. Patients should be informed about common migraine triggers, such as skipped meals, poor sleep, stress, alcohol, menstruation, and specific types of food. Furthermore, patients should be empowered to identify their triggers for more personalized care.[51] Although patients should be advised to avoid any unidentified triggers, it is recognized that, often, triggers cannot be entirely avoided. Therefore, pharmacological management also assumes a crucial role in migraine management. Depending on the severity and frequency of the patient's migraines, a healthcare provider may prescribe a pharmacological agent for migraine prophylaxis. Abortive pharmacological therapies, such as triptans, are recommended for use at the onset of a migraine attack. The interprofessional healthcare team must offer counseling to patients regarding triptan use, emphasizing that eletriptan should be taken at the onset of the migraine attack and not during the aura alone to achieve the most effective results. If eletriptan fails to provide the desired relief for a patient's migraines, the healthcare team should contemplate alternative triptans or other abortive agents. Patients should be informed about potential adverse effects and instructed to seek emergency medical treatment if severe adverse effects are suspected, such as chest pain, pressure or tightness, palpitations, altered mental status, new onset of neurological deficits, symptoms of anaphylaxis, or serotonin syndrome.

The interprofessional healthcare team must offer counseling to patients regarding triptan use, emphasizing that eletriptan should be taken at the onset of the migraine attack and not during the aura alone to achieve the most effective results. If eletriptan fails to provide the desired relief for a patient's migraines, the healthcare team should contemplate alternative triptans or other abortive agents. Patients should be informed about potential adverse effects and instructed to seek emergency medical treatment if severe adverse effects are suspected, such as chest pain, pressure or tightness, palpitations, altered mental status, new onset of neurological deficits, symptoms of anaphylaxis, or serotonin syndrome. Healthcare providers should be vigilant for signs and symptoms of serotonin syndrome in patients concurrently using eletriptan with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) despite the low risk of serotonin syndrome.[52] Patients should be informed about the risk of developing eletriptan overuse headaches, defined as taking eletriptan for 10 or more days in a month. Those who require eletriptan for 10 or more days per month are suitable candidates for prophylactic migraine therapy.[53] Eletriptan is an effective abortive medication for the management of migraines. An evidence-based approach is crucial for managing migraines, necessitating the reassessment of the efficacy of any prophylactic or abortive pharmacological agent. Effectively managing migraines demands collaborative efforts and high-quality communication among interprofessional healthcare team members. Care coordination is vital in ensuring the patient's migraine management therapy is individualized, well-managed, and in the patient's best interest. The healthcare team, including clinicians (MDs, DOs, NPs, and PAs), neurologists or headache specialists, nurses, and pharmacists, should work together to deliver effective, patient-centered care. This collaborative approach aims to minimize adverse events associated with eletriptan and maximize patient safety.